Dondé, Clément
Martinez, Antigona
Sehatpour, Pejman
Patel, Gaurav H.
Kraut, Rebecca
Kantrowitz, Joshua T.
Javitt, Daniel C.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH049334)
Herb and Isabel Stusser Foundation
Article History
Received: 6 March 2019
Accepted: 22 October 2019
First Online: 5 November 2019
Competing interests
: DCJ holds equity in Glytech, LLC; Glytech, Inc; and NeuroRx, Inc. and serves on the board of NeuroRx, Inc. He has served as a paid consultant for Autifony, SK Life Science, Cadence, Pfizer, Phytec, Lundbeck, and Concert. He serves of a DSMB for Biogen and scientific advisory boards for Promentis and Phytec. He receives research funding from Cerevance, Inc. He hold intellectual property for the use of NMDAR agonist in the treatment of schizophrenia (US5,837,730; US5,854,286; US6,162,827; US6,355,681; US6,361,957; US10,265,278) and movement disorders (US8,629,105;9,029,410; US9,029,410; US9,271,966) and for NMDAR antagonists in the treatment of depression (US9,737,531;US9789,093)+corresponding foreign applications. Disclosures have been submitted for use of auditory-based testing in schizophrenia (Columbia Univ) and microglial glycine transport (NKI). All other authors report no conflicts of interest.